

# Innovative Medicines Initiative 2 funding opportunities June 2019

The Innovative Medicines Initiative (IMI) has now launched its 18<sup>th</sup> and 19<sup>th</sup> Calls for proposals under IMI2. The Call gives researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future.

# Why apply?

- Obtain research funding
- Take part in scientifically excellent, patient-centric research
- Join unique consortia involving top teams from industry, academia, SMEs, regulators, and others
- Benefit from the expertise, databases, and infrastructures of consortium partners
- Boost the visibility and status of your organisation in Europe and globally and gain access to new markets

## **IMI2 - Call 18**

IMI2 – Call 18 was launched on 26 June 2019 and is a standard, two-stage Call for proposals. It includes the following topics:

- Central repository of digital pathology slides to support the development of artificial intelligence tools
- Health Outcomes Observatories empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes

# Read the topic texts:

bit.ly/IMI2Call18

**Deadline for short proposals:** 26 September 2019

- Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project
- Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
- Accelerating research & innovation for advanced therapy medicinal products
- Supporting the development of engineered T cells

#### **IMI2 - Call 19**

IMI2 - Call19 is a single stage restricted Call for proposals designed to support further research activities to allow existing successful IMI consortia to build on the achievements of their initial action, move onto the next step of the research challenge, and maximise the impacts of the initial action results. As such the Call is restricted to the initial consortia of actions that fulfil the following two conditions:

### Read the Call text:

bit.ly/IMI2Call19

**Deadline for proposals:** 26 September 2019



- funded through topics launched under Calls for proposals in 2014 and of 2015, since only these actions
  are sufficiently advanced in their implementation to be considered for follow-up research activities;
- derived from topics where the topic text already informed potential applicants about the possibility of a later restricted Call.

In practice, the consortia that meet these criteria are: ADAPT-SMART, BEAt-DKD, DO-IT, HARMONY, INNODIA, ITCC-P4, MOPEAD, NGN-PET, PRISM, RADAR-CNS, RESCEU, RHAPSODY, TransQST.

# How to apply

- The rules and details of how to apply can be found via the Call pages of the IMI website.
- Find out more about both Calls for proposals via our webinars see bit.ly/2W8RhBu
- Follow IMI's tips for applicants see <u>bit.ly/IMItips</u>
- Get advice on finding project partners on our partner search page <u>bit.ly/IMIfindpartners</u>

## **About the Innovative Medicines Initiative**

At IMI, we are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.

We do this by facilitating collaboration between the key players involved in healthcare research.

We are a partnership between the European Union and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), and have a €3.3 billion budget for the period 2014-2020.

Since our launch in 2008, we have launched over 100 projects in areas as diverse as dementia, pain, diabetes, autoimmune disease and antimicrobial resistance as well as tools for drug discovery and development, clinical trial design, and drug and vaccine safety.

#### Stay in touch

Visit the IMI website: www.imi.europa.eu

Sign up to the IMI Newsletter:

bit.ly/IMINewsletter

Follow us on Twitter: **@IMI JU** 

Join the IMI group on LinkedIn: bit.ly/LinkedInIMI

E-mail us:

infodesk@imi.europa.eu

Get support: bit.ly/IMIsupport